Nanoparticle HIV vaccines

Project Details

No safe HIV vaccines have been able to stimulate durable, activated T-cell immunity. We are investigating an exciting HIV vaccination approach using hollow, submicron, delivery vehicles (nanocapsules) assembled using layer-by-layer technology. This is a novel, cross-disciplinary project with the Caruso group at University of Melbourne. Nanocapsules are designed to induce optimal immune responses by protecting antigens from degradation prior to reaching sites of immune activation and activate antigen presenting cells in a way that will initiate anti-viral immune responses. We aim to use controlled-release nanocapsules to stimulate durable CD4 and CD8 T cell responses in vivo.

a

Our work to date (De Rose et al., Advanced Materials, 2008; Sexton et al., ACS Nano, 2009; Chong et al., Biomaterials, 2009) has shown that LbL nanoparticles are efficiently endocytosed by dendritic cells and monocytes in fresh whole blood in a dose dependent manner. Furthermore, we have assembled LbL nanocapsules containing an SIV Gag peptide KP9 and demonstrated that when KP9-nanocapsules are incubated with blood from a Mane-A*10 positive macaque, KP9-specific T cells are stimulated to secrete cytokines (De Rose et al, Advanced Materials, 2008).

These exciting initial findings have been achieved with standard nanoparticles prepared from a range of different polymers that are simple in design and can be prepared rapidly. We are now testing these nanocapsules HIV vaccines in animal models. Further, we are utilising the enormous flexibility of this approach to incorporate novel adjuvants to improve the immunogenicity of these vaccines. In addition, we are also investigating the use of these particles to target anti-HIV inhibitory RNAs to HIV-infected CD4 T cells as a therapeutic strategy. As part of this strategy we have been invesigating novel ways to avoid non-specific uptake of particles - so called "stealth" particles.

Researchers

Dr Rob De Rose, Prof Stephen Kent, Ms Sheilajen Alcantara, Mr Hyon-Xhi Tan in collaboration with Prof Frank Caruso and Dr Jiwei Cui (Univ Melbourne Engineering) and Dr Angus Johnston (now at Monash Pharmacy in Parkville).

Funding

ARC Centre of Excellence award

Research Group

Kent laboratory: HIV vaccines; immune responses to HIV-1; immunotherapy



Faculty Research Themes

Infection and Immunology

School Research Themes

Infection & Immunity, Molecular Mechanisms of Disease



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Microbiology and Immunology

Unit / Centre

Kent laboratory: HIV vaccines; immune responses to HIV-1; immunotherapy